Table 4.
Univariate and multivariate analyses of PFS in EGFR-TKI group.
| Variables | Univariate | p Value a | Multivariate | p Value a |
|---|---|---|---|---|
| HR (95% CI) | aHR (95% CI) | |||
| Age | 0.383 | 0.781 | ||
| ≧65 | Reference | |||
| <65 | 1.967 (0.430–8.999) | 1.369 (0.149–12.594) | ||
| Gender, n (%) | 0.876 | 0.380 | ||
| Male | Reference | |||
| Female | 0.912 (0.286–2.909) | 2.167 (0.386–12.163) | ||
| Smoking status, n (%) | 0.456 | 0.343 | ||
| Never smokers | Reference | |||
| Former or current smokers | 1.550 (0.490–4.904) | 2.384 (0.396–14.343) | ||
| ECOG PS, n (%) | 0.917 | 0.770 | ||
| 0–1 | Reference | |||
| 2–4 | 1.086 (0.229–5.144) | 1.314 (0.210–8.223) | ||
| Stage, n (%) | 0.631 | 0.567 | ||
| Stage 4A | Reference | |||
| Stage 4B | 1.670 (0.207–13.493) | 2.408 (0.119–48.813) | ||
| Baseline EGFR mutation status, n (%) | 0.211 | 0.108 | ||
| Exon 19 deletions | Reference | |||
| Exon 21 L858R | 0.456 (0.133–1.560) | 0.286 (0.062–1.314) | ||
| Bevacizumab | 0.369 | 0.801 | ||
| RP | Reference | |||
| BB | 1.800 (0.499–6.491) | 1.241 (0.230–6.687) |
a
By Cox proportional hazard model.
aHR, adjusted hazard ratio; BB, bevacizumab biosimilar; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio; PFS, progression-free survival; RP, reference product; TKI, tyrosine kinase inhibitor.